A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
NCT00650572
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
ARRY-380, HER2 inhibitor; oral
Sponsor
Seagen Inc.
Collaborators
[object Object]